Jefford, Michael; Kiffer, John D; Somers, Gino; Daniel, Freddy J; Davis, Ian D

doi:10.1111/j.1445-1433.2004.03130.x

Author(s)

Jefford, Michael

Kiffer, John D

Somers, Gino

Daniel, Freddy J

Davis, Ian D

Publication Date

2004-08-01

Abstract

Basal cell carcinoma (BCC) is the most common cancer in the community, although it rarely metastasizes. The literature reports less than 100 patients who have received chemotherapy for metastatic BCC. A further case of this rare disease is reported here. The pattern of disease in the reported patient was similar to that described in the literature, but the patient experienced a long period with untreated metastatic disease compared with that in the literature.The patient was treated with cisplatin in combination with paclitaxel. Literature review suggests this to be the first report of this combination.Rapid symptomatic response was achieved though late neurotoxicity occurred.This regimen is an active combination for the rare patient with metastatic BCC. The combination of carboplatin and paclitaxel causes less neurotoxicity and may therefore be a superior regimen.

Citation

ANZ Journal of Surgery; 74(8): 704-5

Jornal Title

ANZ Journal of Surgery

Link

https://ahro.austin.org.au/austinjspui/handle/1/9792

Title

Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel.

Type of document

Journal Article

Austin Health

Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel.

Files:

Author(s)	Jefford, Michael Kiffer, John D Somers, Gino Daniel, Freddy J Davis, Ian D
Publication Date	2004-08-01
Abstract	Basal cell carcinoma (BCC) is the most common cancer in the community, although it rarely metastasizes. The literature reports less than 100 patients who have received chemotherapy for metastatic BCC. A further case of this rare disease is reported here. The pattern of disease in the reported patient was similar to that described in the literature, but the patient experienced a long period with untreated metastatic disease compared with that in the literature.The patient was treated with cisplatin in combination with paclitaxel. Literature review suggests this to be the first report of this combination.Rapid symptomatic response was achieved though late neurotoxicity occurred.This regimen is an active combination for the rare patient with metastatic BCC. The combination of carboplatin and paclitaxel causes less neurotoxicity and may therefore be a superior regimen.
Citation	ANZ Journal of Surgery; 74(8): 704-5
Jornal Title	ANZ Journal of Surgery
Link	https://ahro.austin.org.au/austinjspui/handle/1/9792
Title	Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel.
Type of document	Journal Article